The nation of Zimbabwe has rejected a major US healthcare agreement valued at $367m (272 million pounds) over five years because of Washington's insistence on sensitive information.
This move became public following a official document from December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson has since explained that the United States was seeking health data for scientific study and profit but was unwilling to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged continued talks to find a agreement agreeable to all parties so the nation's critical HIV programme can continue.
Broader Implications
Zimbabwe's decision comes after a similar situation in Kenya, where a court blocked a similar deal with the US following legal challenges were raised about the safety of citizens' health data.
After returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government agreements to boost transparency and accountability.
According to statements, Sixteen nations in Africa have so far signed these new health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"Effectively, our nation would supply the raw materials for medical research with no certainty that the end products would be accessible to our citizens if a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral deals were upending structures previously established via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to manage future global health emergencies.
"This framework is designed to ensure that when a nation provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing discussions with our American counterparts on how future co-operation might be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts expressed it understood the government's concerns, but recommended that negotiations must proceed given that a large portion of the nation's HIV programmes were funded by external financing.
"Where technical issues arise, including those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," the group commented.
The halted deal underscores the complex challenges between receiving vital foreign assistance and protecting a country's data in an ever more data-driven world.